According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that:
- despite contrary representations to investors, a lack of awareness of RYTELO among health care providers, the weekly monitoring requirement, and seasonality and existing competition would impair Geron’s ability to capitalize on the purportedly significant unmet need for the drug;
- accordingly, the RYTELO launch was unlikely to be as profitable as Geron had led investors to believe;
- as a result, Geron’s business and/or financial prospects were overstated; and
- as a result, Geron’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
